Santaris Pharma
www.santaris.com

Novel cancer drugs (phase II) based on "gene silencing" concept with a proprietary RNA antagonist platform. 367m€ first licensing deal in 2006

Santaris Pharma A/S is a clinical-stage biopharmaceutical company focussed on developing next generation RNA-silencing drugs based on its proprietary LNA® (Locked Nucleic Acid) technology for the treatment of cancer, metabolic disorders and other serious diseases. The Company’s drug pipeline is comprised of novel RNA Antagonist drugs based on its unique LNA® chemistry. LNA drugs, with their high potency and biostability, have the potential to transform the field of RNA inhibiting therapeutics, making specific and effective gene silencing a reality in human medicine. If this potential is realised, even in part, it may be possible to design new drugs to treat a wide variety of human diseases by switching off the expression of harmful genes. Santaris Pharma holds the world wide patent rights to the exploitation of LNA in pharmaceuticals. Presently three drugs are in preclinical or clinical development. The lead drug candidate, SPC2996, is currently undergoing an international, multicentric, phase I/II clinical study in Chronic Lymphocytic Leukemia (CLL).